SG Americas Securities LLC Reduces Position in Anika Therapeutics, Inc. (NASDAQ:ANIK)

SG Americas Securities LLC trimmed its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 34.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,196 shares of the biotechnology company’s stock after selling 3,289 shares during the quarter. SG Americas Securities LLC’s holdings in Anika Therapeutics were worth $102,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC grew its position in Anika Therapeutics by 66.6% in the 3rd quarter. Barclays PLC now owns 32,664 shares of the biotechnology company’s stock valued at $806,000 after acquiring an additional 13,054 shares during the last quarter. Meros Investment Management LP grew its holdings in shares of Anika Therapeutics by 11.6% in the third quarter. Meros Investment Management LP now owns 237,295 shares of the biotechnology company’s stock worth $5,861,000 after purchasing an additional 24,581 shares during the last quarter. Jane Street Group LLC increased its stake in Anika Therapeutics by 54.1% in the 3rd quarter. Jane Street Group LLC now owns 24,351 shares of the biotechnology company’s stock worth $601,000 after buying an additional 8,550 shares during the period. HighTower Advisors LLC lifted its holdings in Anika Therapeutics by 11.3% during the 3rd quarter. HighTower Advisors LLC now owns 15,883 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 1,615 shares in the last quarter. Finally, Stonepine Capital Management LLC boosted its position in Anika Therapeutics by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 189,308 shares of the biotechnology company’s stock valued at $4,676,000 after buying an additional 23,911 shares during the period. 91.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. StockNews.com lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Barrington Research decreased their target price on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday, November 1st.

Anika Therapeutics Stock Performance

NASDAQ ANIK opened at $17.61 on Thursday. Anika Therapeutics, Inc. has a one year low of $15.40 and a one year high of $29.11. The company has a market capitalization of $257.99 million, a price-to-earnings ratio of -2.65 and a beta of 0.89. The company’s 50-day simple moving average is $16.69 and its two-hundred day simple moving average is $20.87.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.